Accessibility helpSkip to navigationSkip to contentSkip to footer


AstraZeneca’s vaccine has saved many thousands of lives. But rare side-effects, and, relative to competitors, lower efficacy against new variants have given it an uncertain outlook. Coupled with a multibillion-euro lawsuit over delivery shortfalls, the UK pharma group’s future role in the ongoing battle against Covid-19 is under scrutiny

© FT montage

International Edition